Find Clinical Trials

All CategoriesMedications / Interventions»Mm»Muromonab-CD



Join Paid Clinical Trials



  • Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   PSA Progression;   Stage IV Prostate Adenocarcinoma AJCC v7
    Interventions:   Biological: HER2Bi-Armed Activated T Cells;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD19 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive
    Interventions:   Biological: Blinatumomab;   Drug: Ibrutinib
    Sponsors:   Brian Jonas;   National Cancer Institute (NCI);   Pharmacyclics LLC.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   CD19-Positive Neoplastic Cells Present;   Mixed Phenotype Acute Leukemia;   Mixed Phenotype Acute Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   CD22 Positive;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Biological: Inotuzumab Ozogamicin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD19 Positive;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mediastinal Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Mediastinal Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma
    Interventions:   Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   BCR/ABL1 Fusion Protein Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

Login to Get Started